Host |
Mouse |
Clone |
JC/70A |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Pepsin |
Positive control |
Tonsil |
Dilution |
1:10 - 1:25 |
Isotype |
Mouse IgG1 |
Localization |
Cell Membrane |
CD31 (PECAM-1)
|
Diagnostic Biosystems |
JC/70A |
0.1 ml |
Concentrate |
CE/IVD |
MOB034-01 |
-
|
Host |
Mouse |
Clone |
JC/70A |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Pepsin |
Positive control |
Tonsil |
Dilution |
1:10 - 1:25 |
Isotype |
Mouse IgG1 |
Localization |
Cell Membrane |
CD31 (PECAM-1)
|
Diagnostic Biosystems |
JC/70A |
0.5 ml |
Concentrate |
CE/IVD |
MOB034-05 |
-
|
Host |
Mouse |
Clone |
JC/70A |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
Pepsin |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
Mouse IgG1 |
Localization |
Cell Membrane |
CD31 (PECAM-1)
|
Diagnostic Biosystems |
JC/70A |
6 ml |
Ready-to-use |
CE/IVD |
PDM020 |
-
|
Host |
Mouse |
Clone |
CO.3E1D4 |
Format |
Purified |
Method |
FL |
Isotype |
Mouse IgG2a |
Immunogen |
Sheep leucocytes |
CD31 (PECAM-1) - FITC
|
Zytomed Systems GmbH |
CO.3E1D4 |
100 µg |
Purified |
RUO |
603-0798C |
-
|
Host |
Mouse |
Clone |
PWS44 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Myeloid leukemia |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG2b |
Localization |
Cytoplasm and Cell Membrane |
CD33
|
Biocare Medical |
PWS44 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3116A |
-
|
Host |
Mouse |
Clone |
PWS44 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Myeloid leukemia |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG2b |
Localization |
Cytoplasm and Cell Membrane |
CD33
|
Biocare Medical |
PWS44 |
1 ml |
Concentrate |
CE/IVD |
ACI3116C |
-
|
Host |
Mouse |
Clone |
PWS44 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Myeloid leukemia |
Dilution |
- |
Isotype |
Mouse IgG2b |
Localization |
Cytoplasm and Cell Membrane |
CD33
|
Biocare Medical |
PWS44 |
6 ml |
Ready-to-use |
CE/IVD |
API3116AA |
-
|
Host |
Mouse |
Clone |
QBEnd/10 |
Format |
ready-to-use |
Method |
IHC, FFPE |
Pretreatment |
Citrate o EDTA |
Positive control |
Tonsil, skin or angiosarcoma |
Dilution |
--- |
Isotype |
IgG1 |
Immunogen |
CD34 |
Localization |
Cell surface and cytoplasmic |
CD34
|
Biocare Medical |
QBEnd/10 |
6 ml |
ready-to-use |
CE/IVD |
AVI084G |
-
|
Host |
Mouse |
Clone |
QBend/10 |
Format |
Concentrate |
Method |
F, P |
Positive control |
Tonsil |
Dilution |
1:25 - 1:100 |
Isotype |
Mouse IgG1 kappa |
Localization |
Cell Membrane |
CD34
|
Diagnostic Biosystems |
QBend/10 |
1 ml |
Concentrate |
CE/IVD |
MOB098 |
-
|
Host |
Mouse |
Clone |
QBend/10 |
Format |
Concentrate |
Method |
F, P |
Positive control |
Tonsil |
Dilution |
1:25 - 1:100 |
Isotype |
Mouse IgG1 kappa |
Localization |
Cell Membrane |
CD34
|
Diagnostic Biosystems |
QBend/10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB098-01 |
-
|
Host |
Mouse |
Clone |
QBend/10 |
Format |
Concentrate |
Method |
F, P |
Positive control |
Tonsil |
Dilution |
1:25 - 1:100 |
Isotype |
Mouse IgG1 kappa |
Localization |
Cell Membrane |
CD34
|
Diagnostic Biosystems |
QBend/10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB098-05 |
-
|
Host |
Mouse |
Clone |
QBend/10 |
Format |
Ready-to-use |
Method |
F, P |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
Mouse IgG1 kappa |
Localization |
Cell Membrane |
CD34
|
Diagnostic Biosystems |
QBend/10 |
6 ml |
Ready-to-use |
CE/IVD |
PDM050 |
-
|
Host |
Mouse |
Clone |
QBEnd-10 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Hemangioma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 /κ |
Immunogen |
Detergent solubilized vesicular suspension prepared from a perfusate of human term placenta |
Localization |
Cell membrane/Cytoplasm |
CD34
|
Zeta Corporation |
QBEnd-10 |
1.0 ml |
Concentrate |
CE/IVD |
Z2063ML |
-
|
Host |
Mouse |
Clone |
QBEnd-10 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Positive control |
Hemangioma. |
Dilution |
- |
Isotype |
IgG1 /κ |
Immunogen |
Detergent solubilized vesicular suspension prepared from a perfusate of human term placenta |
Localization |
Cell membrane/Cytoplasm |
CD34
|
Zeta Corporation |
QBEnd-10 |
7 ml |
Ready-to-use |
CE/IVD |
Z2063MP |
-
|
Host |
Mouse |
Clone |
QBEnd-10 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Hemangioma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 /κ |
Immunogen |
Detergent solubilized vesicular suspension prepared from a perfusate of human term placenta |
Localization |
Cell membrane/Cytoplasm |
CD34
|
Zeta Corporation |
QBEnd-10 |
0.5 ml |
Concentrate |
CE/IVD |
Z2063MS |
-
|
Host |
Mouse |
Clone |
QBEnd-10 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Hemangioma. |
Dilution |
1:100 - 1:200 |
Isotype |
IgG1 /κ |
Immunogen |
Detergent solubilized vesicular suspension prepared from a perfusate of human term placenta |
Localization |
Cell membrane/Cytoplasm |
CD34
|
Zeta Corporation |
QBEnd-10 |
0.1 ml |
Concentrate |
CE/IVD |
Z2063MT |
-
|
Host |
Rat |
Clone |
MEC14.7 |
Format |
Purified |
Method |
IP, FL |
Isotype |
Rat IgG2a |
CD34 (Endothelial Cell) (Low Endotoxin)
|
Zytomed Systems GmbH |
MEC14.7 |
500 µg |
Purified |
RUO |
603-0832 |
-
|
Host |
Mouse |
Clone |
QBEND/10 |
Format |
Purified |
Method |
FL |
Isotype |
Mouse IgG1 |
Immunogen |
Human endothelial cell membrane vesicles |
CD34 (Endothelial Cell) - FITC
|
Zytomed Systems GmbH |
QBEND/10 |
100 Tests |
Purified |
RUO |
603-0845C |
-
|
Host |
Rabbit |
Clone |
SP191 |
Method |
IHC-P |
Dilution |
1:100 |
CD35
|
Zytomed Systems GmbH |
SP191 |
1 ml |
- |
RUO |
503-4914 |
-
|
Host |
Mouse |
Clone |
E11 |
Format |
Purified |
Method |
F, P, WB, FL |
Pretreatment |
Citrate |
Positive control |
Human Tonsil |
Dilution |
1-10 µg/mL (P) |
Isotype |
Mouse IgG1 |
Immunogen |
Human acute monocytic leukemia cells |
CD35 (CR1)
|
Zytomed Systems GmbH |
E11 |
100 µg |
Purified |
RUO |
603-0851 |
-
|
Host |
Rabbit |
Clone |
SP149 |
Format |
Concentrate |
Method |
P, FL |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide corresponding to the C-terminus of human CD38 protein. |
Localization |
Cell membrane |
CD38
|
Zytomed Systems GmbH |
SP149 |
0.1 ml |
Concentrate |
RUO |
503-4490 |
-
|
Host |
Rabbit |
Clone |
SP149 |
Format |
Concentrate |
Method |
P, FL |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide corresponding to the C-terminus of human CD38 protein. |
Localization |
Cell membrane |
CD38
|
Zytomed Systems GmbH |
SP149 |
0.5 ml |
Concentrate |
RUO |
503-4492 |
-
|
Host |
Rabbit |
Clone |
SP149 |
Format |
Concentrate |
Method |
P, FL |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide corresponding to the C-terminus of human CD38 protein. |
Localization |
Cell membrane |
CD38
|
Zytomed Systems GmbH |
SP149 |
1 ml |
Concentrate |
RUO |
503-4494 |
-
|
Host |
Rabbit |
Clone |
ZR351 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:100 - 1:200 |
Isotype |
Rabbit IgG |
Immunogen |
Peptide derived from the C-terminus of human CD38 protein |
Localization |
Cytoplasm |
CD38
|
Zeta Corporation |
ZR351 |
1 ml |
Concentrate |
CE/IVD |
Z2610RL |
-
|
Host |
Rabbit |
Clone |
ZR351 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
Rabbit IgG |
Immunogen |
Peptide derived from the C-terminus of human CD38 protein |
Localization |
Cytoplasm |
CD38
|
Zeta Corporation |
ZR351 |
7 ml |
Ready-to-use |
CE/IVD |
Z2610RP |
-
|
Host |
Rabbit |
Clone |
ZR351 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:100 - 1:200 |
Isotype |
Rabbit IgG |
Immunogen |
Peptide derived from the C-terminus of human CD38 protein |
Localization |
Cytoplasm |
CD38
|
Zeta Corporation |
ZR351 |
0.5 ml |
Concentrate |
CE/IVD |
Z2610RS |
-
|
Host |
Rabbit |
Clone |
ZR351 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:100 - 1:200 |
Isotype |
Rabbit IgG |
Immunogen |
Peptide derived from the C-terminus of human CD38 protein |
Localization |
Cytoplasm |
CD38
|
Zeta Corporation |
ZR351 |
0.1 ml |
Concentrate |
CE/IVD |
Z2610RT |
-
|
Host |
Mouse |
Clone |
AT13/5 |
Format |
Purified |
Method |
F, IP, FL |
Isotype |
Mouse IgG1 |
CD38 (Azide Free)
|
Zytomed Systems GmbH |
AT13/5 |
1 mg |
Purified |
RUO |
603-0870F |
-
|
Host |
Mouse |
Clone |
GRP-P |
Format |
Lyophilised |
Method |
FL |
Isotype |
Mouse IgG1 |
Immunogen |
Human red blood cells and platelets |
CD42a - RPE
|
Zytomed Systems GmbH |
GRP-P |
100 Tests |
Lyophilised |
RUO |
603-0925E |
-
|
Host |
Rabbit |
Clone |
SP202 |
Format |
Concentrate |
Reactivity |
MS |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Bone Marrow, Spleen |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide from human CD42b protein |
Localization |
Cell Membrane |
CD42b
|
Zytomed Systems GmbH |
SP202 |
0.1 ml |
Concentrate |
RUO |
503-5020 |
-
|
Host |
Rabbit |
Clone |
SP202 |
Format |
Concentrate |
Reactivity |
MS |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Bone Marrow, Spleen |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide from human CD42b protein |
Localization |
Cell Membrane |
CD42b
|
Zytomed Systems GmbH |
SP202 |
0.5 ml |
Concentrate |
RUO |
503-5022 |
-
|
Host |
Rabbit |
Clone |
SP202 |
Format |
Concentrate |
Reactivity |
MS |
Method |
P |
Pretreatment |
EDTA |
Positive control |
Bone Marrow, Spleen |
Dilution |
1:100 |
Isotype |
Rabbit IgG |
Immunogen |
Synthetic peptide from human CD42b protein |
Localization |
Cell Membrane |
CD42b
|
Zytomed Systems GmbH |
SP202 |
1 ml |
Concentrate |
RUO |
503-5024 |
-
|
Host |
Mouse |
Clone |
DF-T1 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate (optional) |
Positive control |
Tonsil |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 kappa |
Immunogen |
Pluripotent human cell line K562 |
Localization |
Cell Membrane |
CD43
|
Zytomed Systems GmbH |
DF-T1 |
1 ml |
Concentrate |
RUO |
MSK065 |
-
|
Host |
Mouse |
Clone |
DF-T1 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate (optional) |
Positive control |
Tonsil |
Dilution |
1:50 - 1:100 |
Isotype |
Mouse IgG1 kappa |
Immunogen |
Pluripotent human cell line K562 |
Localization |
Cell Membrane |
CD43
|
Zytomed Systems GmbH |
DF-T1 |
0.5 ml |
Concentrate |
RUO |
MSK065-05 |
-
|
Host |
Mouse |
Clone |
DF-T1 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Tonsil, CLL/SLL, or lymph node. |
Dilution |
1:100 |
Isotype |
IgG1 /κ |
Immunogen |
Stimulated human leukocytes |
Localization |
Cell membrane |
CD43
|
Zeta Corporation |
DF-T1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2032ML |
-
|
Host |
Mouse |
Clone |
DF-T1 |
Format |
Ready-to-use |
Reactivity |
- |
Method |
P |
Positive control |
Tonsil, CLL/SLL, or lymph node. |
Dilution |
- |
Isotype |
IgG1 /κ |
Immunogen |
Stimulated human leukocytes |
Localization |
Cell membrane |
CD43
|
Zeta Corporation |
DF-T1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2032MP |
-
|
Host |
Mouse |
Clone |
DF-T1 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Tonsil, CLL/SLL, or lymph node. |
Dilution |
1:100 |
Isotype |
IgG1 /κ |
Immunogen |
Stimulated human leukocytes |
Localization |
Cell membrane |
CD43
|
Zeta Corporation |
DF-T1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2032MS |
-
|
Host |
Mouse |
Clone |
DF-T1 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Tonsil, CLL/SLL, or lymph node. |
Dilution |
1:100 |
Isotype |
IgG1 /κ |
Immunogen |
Stimulated human leukocytes |
Localization |
Cell membrane |
CD43
|
Zeta Corporation |
DF-T1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2032MT |
-
|
Host |
Mouse |
Clone |
156-3C11 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Diva modified Citrate pH 6.2 |
Positive control |
Tonsil, breast cancer |
Dilution |
1:150 - 1:300 |
Isotype |
Mouse IgG2a |
Localization |
Cell membrane, cytoplasmic |
CD44
|
Biocare Medical |
156-3C11 |
0.1 ml |
Concentrate |
CE/IVD |
CM318A |
-
|
Host |
Mouse |
Clone |
156-3C11 |
Format |
Concentrate |
Method |
P |
Pretreatment |
Diva modified Citrate pH 6.2 |
Positive control |
Tonsil, breast cancer |
Dilution |
1:150 - 1:300 |
Isotype |
Mouse IgG2a |
Localization |
Cell membrane, cytoplasmic |
CD44
|
Biocare Medical |
156-3C11 |
0.5 ml |
Concentrate |
CE/IVD |
CM318B |
-
|
Host |
Mouse |
Clone |
156-3C11 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:25 - 1:75 |
Isotype |
Mouse IgG2a |
Localization |
Cell Membrane |
CD44
|
Diagnostic Biosystems |
156-3C11 |
1 ml |
Concentrate |
CE/IVD |
MOB256 |
-
|
Host |
Mouse |
Clone |
156-3C11 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:25 - 1:75 |
Isotype |
Mouse IgG2a |
Localization |
Cell Membrane |
CD44
|
Diagnostic Biosystems |
156-3C11 |
0.1 ml |
Concentrate |
CE/IVD |
MOB256-01 |
-
|
Host |
Mouse |
Clone |
156-3C11 |
Format |
Concentrate |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
1:25 - 1:75 |
Isotype |
Mouse IgG2a |
Localization |
Cell Membrane |
CD44
|
Diagnostic Biosystems |
156-3C11 |
0.5 ml |
Concentrate |
CE/IVD |
MOB256-05 |
-
|
Host |
Mouse |
Clone |
156-3C11 |
Format |
Ready-to-use |
Method |
F, P |
Pretreatment |
Citrate |
Positive control |
Tonsil |
Dilution |
- |
Isotype |
Mouse IgG2a |
Localization |
Cell Membrane |
CD44
|
Diagnostic Biosystems |
156-3C11 |
6 ml |
Ready-to-use |
CE/IVD |
PDM172 |
-
|
Host |
Mouse |
Clone |
156-3C11 |
Format |
Ready-to-use |
Method |
P |
Pretreatment |
Diva modified Citrate pH 6.2 |
Positive control |
Tonsil, breast cancer |
Dilution |
- |
Isotype |
Mouse IgG2a |
Localization |
Cell membrane, cytoplasmic |
CD44
|
Biocare Medical |
156-3C11 |
6 ml |
Ready-to-use |
CE/IVD |
PM318AA |
-
|
Host |
Mouse |
Clone |
VFF-7 |
Format |
Purified |
Method |
F, P, WB, FL |
Pretreatment |
Citrate |
Dilution |
1:200 (P) |
Isotype |
Mouse IgG1 |
CD44v6
|
Zytomed Systems GmbH |
VFF-7 |
100 µg |
Purified |
RUO |
603-0983 |
-
|
Host |
Mouse |
Clone |
VFF-7 |
Format |
Purified |
Method |
FL |
Isotype |
Mouse IgG1 |
CD44v6 - FITC
|
Zytomed Systems GmbH |
VFF-7 |
100 Tests |
Purified |
RUO |
603-0985C |
-
|
Host |
Rat |
Clone |
YW62.3 |
Format |
Purified |
Method |
F, IP, FL |
Isotype |
Rat IgG2b |
Immunogen |
Mouse spleen cells |
CD45 (LCA)
|
Zytomed Systems GmbH |
YW62.3 |
100 µg |
Purified |
RUO |
603-0993 |
-
|
Host |
Rabbit |
Clone |
ZR361 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Tonsil or lymph node |
Dilution |
1:100 - 1:200 |
Isotype |
IgG |
Immunogen |
Recombinant full-length human PTPRC protein |
Localization |
Cell surface and cytoplasm |
CD45 (LCA)
|
Zeta Corporation |
ZR361 |
1 ml |
Concentrate |
CE/IVD |
Z2737RL |
-
|
Host |
Rabbit |
Clone |
ZR361 |
Format |
Concentrate |
Reactivity |
- |
Method |
P |
Positive control |
Tonsil or lymph node |
Dilution |
- |
Isotype |
IgG |
Immunogen |
Recombinant full-length human PTPRC protein |
Localization |
Cell surface and cytoplasm |
CD45 (LCA)
|
Zeta Corporation |
ZR361 |
7 ml |
Concentrate |
CE/IVD |
Z2737RP |
-
|